Context Therapeutics Updates Corporate Presentation (Reg FD)

What Happened
Context Therapeutics Inc. filed a Current Report on Form 8‑K on August 5, 2026 (Item 7.01, Regulation FD Disclosure) to announce an updated corporate presentation for use in meetings with investors, analysts and others. A copy of the presentation is included as Exhibit 99.1 and the report is signed by CEO Martin A. Lehr.

Key Details

• Filed on August 5, 2026 under Item 7.01 (Regulation FD Disclosure).
• Exhibit 99.1: "Context Therapeutics Inc. Corporate Presentation — August 2026" was furnished and incorporated by reference.
• Presentation is intended for investor/analyst meetings and other similar uses.
• Report signed by Martin A. Lehr, Chief Executive Officer.

Why It Matters
This 8‑K provides investors with the company’s most recent investor-facing materials; reviewing Exhibit 99.1 lets shareholders see Context’s current messaging on strategy, pipeline and milestones. The filing is a disclosure update (not a financial results or executive-change report), so investors should read the attached presentation for any substantive updates but note the 8‑K itself does not report earnings or other material financial items.